THE ONLY NOVEL*
ERLEADA® OFFERS MORE FLEXIBILITY FOR YOUR PATIENTS1
ONE 240 MG TABLET OR FOUR 60 MG TABLETS—ADMINISTERED ORALLY ONCE DAILY†
60 mg tablet
4 tablets, once daily
(~17 mm x 9 mm)
240 mg tablet
1 tablet, once daily
(~21 mm x 10 mm)
Size comparison of 60 mg
and 240 mg tablets
Tablets shown are not actual size.5
†Patients receiving ERLEADA® should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.
- Provides alternate methods of administration for patients who have difficulty swallowing tablets whole or have a feeding tube
- Does not require concurrent chemotherapy
†Patients receiving ERLEADA® should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.
No initial dose adjustments needed for renal or hepatic impairment‡1
‡ERLEADA® has not been evaluated in
patients with severe renal or hepatic impairment.
No need for concurrent chemotherapy1
Do not crush or split tablets. ERLEADA® can be taken with or without food§
§For alternate methods of administration, tablets may be dispersed according to the instructions for alternate dosing methods.
DOSAGE MODIFICATION
If Grade 3 or greater adverse reactions or other intolerable adverse reactions occur, withhold ERLEADA®. Consider permanent discontinuation of ERLEADA® for Grade 3 or 4 cerebrovascular and ischemic cardiovascular events. Permanently discontinue ERLEADA® for confirmed SCARs or for other Grade 4 skin reactions. For other adverse reactions, when symptoms improve to ≤Grade 1 or original grade, resume ERLEADA® at the same dose or a reduced dose (180 mg or 120 mg), if warranted.1
For detailed instructions on administration, please see the full ERLEADA® Prescribing Information.
ERLEADA® IS THE ONLY NOVEL ANDROGEN RECEPTOR INHIBITOR WITH 240 MG, SINGLE-TABLET, ONCE-DAILY DOSING1-3
FDA-approved androgen receptor inhibitors|| for the treatment of mCSPC¶1-3
||Patients receiving these ARI therapies should also receive a GnRH analog concurrently or should have had bilateral orchiectomy.
¶Product comparisons with regard to efficacy and safety cannot be made in the absence of head-to-head clinical studies. This presentation is not intended to compare the relative efficacy or safety of the treatments. Please refer to the full Prescribing Information of each agent for dosage and administration.
#For detailed instructions on administration, please see the full ERLEADA® Prescribing Information.
THE ONLY ANDROGEN RECEPTOR INHIBITOR WITH THE CONVENIENCE OF ALTERNATE METHODS OF ADMINISTRATION1-3
ERLEADA® offers the convenience of alternate methods of administration for patients who have difficulty swallowing tablets whole or who have a feeding tube**1
ERLEADA® 240 mg Tablet Alternate Methods of Administration
Orange juice
Applesauce
Noncarbonated water
Feeding tube
ERLEADA® 60 mg Tablets Alternate Method of Administration
Applesauce
**For detailed instructions on administration, please see the full ERLEADA® Prescribing Information.
Instructions for alternate dosing methods
Starting and Staying on ERLEADA® Guide
YOUR PATIENT’S TREATMENT JOURNEY STARTS HERE
- Financial Assistance: Education and resources that may be able to help your patients save on potential out-of-pocket medication costs
- Medication & Disease Education: Help patients gain a better understanding of their disease, their current treatment, and how to have meaningful conversations with loved ones and their care team during upcoming visits
- Practical Needs & General Well-Being: Learn lifestyle and coping skills to help manage stress and get connected to the resources your patients need, including support groups and transportation assistance
ADT = androgen deprivation therapy; ARI = androgen receptor inhibitor; BID = twice a day; GnRH = gonadotropin-releasing hormone; mCSPC = metastatic castration-sensitive prostate cancer; QD = once a day.
REFERENCES:
- ERLEADA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
- NUBEQA® [Prescribing Information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.
- XTANDI® [Prescribing Information]. Northbrook, IL: Astellas Pharma US, Inc.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.1.2023. ©National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed March 11, 2023. To view the most recent and complete version of the guideline, go to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- Data on file. Janssen Biotech, Inc.